Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 15/20 | 0.67 |
| ▸ | BRAF | P15056 | 9/20 | 0.67 |
| ▸ | KDR | P35968 | 5/20 | 0.67 |
| ▸ | RET | P07949 | 3/20 | 0.67 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.67 |
| ▸ | ABL1 | P00519 | 2/20 | 0.67 |
| ▸ | HTR1A | P08908 | 2/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | KIT | P10721 | 2/20 | 0.67 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.67 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.67 |
| ▸ | FLT1 | P17948 | 2/20 | 0.67 |
| ▸ | MAOA | P21397 | 2/20 | 0.67 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.67 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.67 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.67 |
| ▸ | TTK | P33981 | 2/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1702120 | 0.99 | RAF1 (0.66) | RAF1BRAFKDRRETRIPK2 | |
| Hydrochloric Acid SCHEMBL1702492 | 0.98 | RAF1 (0.65) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL1702479 | 0.96 | RAF1 (0.63) | RAF1BRAFKDRRETRIPK2 | |
| Sulfuric Acid SCHEMBL2043327 | 0.96 | RAF1 (0.63) | RAF1BRAFKDRRETRIPK2 | |
| Maleic Acid SCHEMBL1702367 | 0.95 | RAF1 (0.61) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL2045624 | 0.94 | RAF1 (0.60) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL14481187 | 0.94 | RAF1 (0.59) | RAF1BRAFKDRRETRIPK2 | |
| Sorafenib SCHEMBL16699243 | 0.93 | RAF1 (0.81) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL5079975 | 0.93 | RAF1 (0.69) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL6012038 | 0.92 | RAF1 (0.61) | RAF1BRAFKDRRETRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 461 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2786750-B2 | AGENT FOR REDUCING ADVERSE SIDE EFFECTS OF KINASE INHIBITOR | EA PHARMA CO LTD (JP) | 2023-06-28 | — | — | EP | claimed |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | claimed |
| US-20200155594-A1 | HORNERIN: A NOVEL NON-VEGF MEDIATED ANGIOGENIC PROTEIN EXPRESSED IN BOTH HUMAN AND MOUSE ANGIOGENIC ENDOTHELIAL CELLS AND HUMAN PANCREATIC CANCER CELLS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-05-21 | — | — | US | claimed |
| US-20180169067-A1 | COMBINATION DRUG THERAPIES FOR CANCER AND METHODS OF MAKING AND USING THEM | VICUS THERAPEUTICS LLC (US) | 2018-06-21 | — | — | US | claimed |
| WO-2018075865-A1 | COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Glialogix, Inc. (US) | 2018-04-26 | — | — | WO | claimed |
| US-9889120-B2 | Combination drug therapies for cancer and methods of making and using them | VICUS THERAPEUTICS, LLC (US) | 2018-02-13 | — | — | US | claimed |
| US-20170202806-A1 | COMBINATION DRUG THERAPIES FOR CANCER AND METHODS OF MAKING AND USING THEM | VICUS THERAPEUTICS LLC (US) | 2017-07-20 | — | — | US | claimed |
| US-20170165240-A1 | NEW STRATEGIES FOR TREATING MELANOMA | Université Libre de Bruxelles (BE) | 2017-06-15 | — | — | US | claimed |
| US-20160228513-A1 | TREATMENT OF MELANOMA WITH INTERFERON-BETA AND RAS-RAF-MEK-ERK INHIBITOR COMBINATION THERAPY | BIOGEN MA INC. (US) | 2016-08-11 | — | — | US | claimed |
| EP-2786750-B1 | AGENT FOR REDUCING ADVERSE SIDE EFFECTS OF KINASE INHIBITOR | AJINOMOTO KK (JP) | 2016-06-08 | — | — | EP | claimed |
| EP-2298311-B1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-05-09 | — | — | EP | claimed |
| WO-2012052757-A1 | TUMOUR PHENOTYPE PATIENT SELECTION METHOD | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | WO | claimed |
| EP-2440531-A2 | POLYMORPHS OF 4-[4-[[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]CARBAMOYLAMINO]PHENOXY]-N-METHYL-PYRIDINE-2-CARBOXAMIDE | Ratiopharm GmbH (DE) | 2012-04-18 | — | — | EP | claimed |
| US-20120082647-A1 | INTERFERON-BETA FOR USE AS MONOTHERAPY OR IN COMBINATION WITH OTHER CANCER THERAPIES | BIOGEN MA INC. | 2012-04-05 | — | — | US | claimed |
| WO-2010142678-A2 | POLYMORPHS OF 4-[4-[[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]CARBAMOYLAMINO]PHENOXY]-N-METHYL-PYRIDINE-2-CARBOXAMIDE | RATIOPHARM GMBH (DE) | 2010-12-16 | — | — | WO | claimed |
| US-20080108672-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-05-08 | — | — | US | claimed |
| US-20070031338-A1 | Embolized cryoablation for treatment of tumors | ZABINSKI PETER P | 2007-02-08 | — | — | US | claimed |
| CN-1625602-A | Method for selecting drug sensitivity decision factor and method for predetermining drug sensitivity using the selected factor | HOFFMANN LA ROCHE (CH) | 2005-06-08 | — | — | CN | claimed |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER CORPORATION | 2002-04-11 | — | — | US | claimed |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108672-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885KDR 567/4885 |
| US-20170165240-A1 | NEW STRATEGIES FOR TREATING MELANOMA | TP53, BRAF, TP53BP1 | RAF1 5/4885BRAF 2/4885KDR 1139/4885 |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885KDR 567/4885 |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885KDR 567/4885 |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | RAF1 37/4885BRAF 42/4885KDR 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.